---
title: Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer
nct_id: NCT02491580
overall_status: COMPLETED
sponsor: Uppsala University
study_type: OBSERVATIONAL
primary_condition: Neoplasms
countries: Sweden
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02491580.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02491580"
ct_last_update_post_date: 2015-07-08
last_seen_at: "2026-05-12T06:12:52.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer

**NCT ID:** [NCT02491580](https://clinicaltrials.gov/study/NCT02491580)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2370
- **Lead Sponsor:** Uppsala University
- **Conditions:** Neoplasms, Kidney Failure
- **Start Date:** 2014-10
- **Completion Date:** 2015-06
- **CT.gov Last Update:** 2015-07-08

## Brief Summary

Patients with previous malignancies have increasingly been accepted for renal transplantation. However, post-transplant malignancy risk and survival rates of these patients are unknown. Our aim was to assess if previous malignancies pose an unnecessarily high risk of post-transplant malignant tumours and if the organs as a resource are too limited for investment in this patient group.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Kidney transplanted patients from January 1982 through December 2013 with or without a pre transplant cancer.

Exclusion Criteria:

* Simultaneous kidney+pancreas transplantation.
* Islet cell transplanted patients
* Undiagnosed malignancies at the time of transplantation
* Death within a week after transplantation
* First transplantation at another hospital
```

## Arms

- **KTx Uppsala** — Patients who have received a kidney transplant in Uppsala.
- **KTx Europe** — Patients who have received a kidney transplant in Uppsala.

## Primary Outcomes

- **Incidence of post-transplant cancer** _(time frame: Up to 33 years starting in January 1982.)_

## Secondary Outcomes

- **Patient survival** _(time frame: Up to 33 years starting in January 1982.)_
- **Cancer-induced mortality** _(time frame: Up to 33 years starting in January 1982.)_

## Locations (1)

- Uppsala University, Department of Surgical Sciences, Section of Transplantation Surgery, Uppsala, Sweden

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.uppsala university, department of surgical sciences, section of transplantation surgery|uppsala||sweden` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02491580.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02491580*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*